Document text
Principal Investigator: Cristina Canavesi
Organization: LIGHTOPTECH CORPORATION
Fiscal Year: 2024
Award: $886,898
Funding agency: National Eye Institute
The cornea, the outermost window of our visual system, is vulnerable to various types of infections and diseases.
Corneal disease is one of the leading causes of visual deficiency and blindness, and is considered the second
major cause of blindness in developing countries. There are nearly 5 million bilaterally corneal blind persons
worldwide, and an estimated 23 million people affected by unilateral corneal blindness globally. In a conservative
estimate, corneal diseases affect nearly 300,000 people in the United States, with Fuchs’ dystrophy affecting
4% of people aged over 40. Given the large prevalence of corneal disease and the near-impossibility of
performing biopsy, high-definition corneal imaging is needed to assist clinical diagnosis, evaluate progression of
diseases, and treatment. Additionally, the cornea is the most commonly transplanted tissue worldwide.
Gabor-domain optical coherence microscopy (GDOCM) is a high-resolution, non-invasive imaging technology
that can visualize microscopic structures in vivo in 3D. Preliminary data suggest that GDOCM has the following
key advantages over existing corneal imaging techniques, which include specular and confocal microscopy: 1)
10-100x increase in field of view – this will lead to more accurate qualification of the corneal tissue, since a larger
area can be assessed; 2) simultaneous measure of corneal thickness, quantification of endothelial cell density,
as well as identification of morphological variations due to corneal disease – this will lead to full corneal evaluation
in one instrument; 3) 3D imaging capability at the cellular level of the mosaic of translucent corneal cells – this
will enable a detailed understanding the volumetric progression of the diseases.
We have assembled an exceptionally strong team of clinical investigators to collaborate on this proposal, and
with their help we have identified four use cases for clinical application of our dual-imaging technology to image
the cornea with volumetric cellular-resolution. We envision that in the future the dual OCT (optical coherence
tomography) and GDOCM instrument enabled by this Phase II SBIR proposal will provide an image-guidance
method to assist clinicians in the assessment and treatment of corneal diseases and other diseases affecting
the anterior segment of the eye, including diabetes and glaucoma.
Terms: <3-D><3-D Imaging><3-D visualization><3-Dimensional><3-dimensional visualization><3D><3D imaging><3D visualization><Address><Affect><Anterior Eye Segment><Anterior eyeball segment structure><Area><Bilateral><Biopsy><Blindness><Body Tissues><Cell Body><Cell Components><Cell Density><Cell Structure><Cells><Cellular Structures><Characteristics><Clinic><Clinical><Clinical Data><Clinical Investigator><Collaborations><Confocal Microscopy><Cornea><Corneal Diseases><Corneal Disorder><Data><Data Collection><Developing Countries><Developing Nations><Diabetes Mellitus><Diagnosis><Diagnostic><Diminished Vision><Disease><Disease Progression><Disorder><Doppler OCT><Dry Eye Syndromes><Dry eye disease><Endothelial Cells><Evaluation><Eye><Eye Banks><Eyeball><Fuchs endothelial corneal dystrophy><Fuchs' Endothelial Dystrophy><Fuchs' dystrophy><Future><Glaucoma><Goals><Gold><Grant><Health><I-Corps><Image><Image Analyses><Image Analysis><Imaging Device><Imaging Instrument><Imaging Procedures><Imaging Technics><Imaging Techniques><Imaging Tool><Imaging technology><Infection><Innovation Corps><Keratitis><Keratoconjunctivitis Sicca><Leanness><Legal patent><Less-Developed Countries><Less-Developed Nations><Licensing><Low Vision><Machine Learning><Measurement><Measures><Methods><Microscope><Microscopic><Microscopy><Monitor><Morphology><NIH><National Institutes of Health><OCT Tomography><Ophthalmology><Optical Coherence Tomography><Optics><Pain><Painful><Partial Sight><Patents><Pathology><Patients><Persons><Phase><Prevalence><Process><Qualifying><Reduced Vision><Research><Resolution><Retina><Rights><SBIR><Sampling><Small Business Innovation Research><Small Business Innovation Research Grant><Standardization><Structure><Subnormal Vision><Survey Instrument><Surveys><Systems Development><Technology><Thick><Thickness><Thinness><Third-World Countries><Third-World Nations><Three-Dimensional Imaging><Time><Tissue Transplantation><Tissues><Under-Developed Countries><Under-Developed Nations><United States><United States National Institutes of Health><Universities><Variant><Variation><Visual><Visual System><Visual impairment><Visualization><Visually Impaired Persons><aged><blind individual><blind people><clinical applicability><clinical application><clinical diagnosis><clinical translation><clinically translatable><commercial application><commercialization><cornea disorder><corneal><data acquisition><data acquisitions><data management><developing country><developing nation><diabetes><dystrophia epithelialis corneae><glaucomatous><image evaluation><image guidance><image guided><image interpretation><image processing><image-based method><imaging><imaging capabilities><imaging method><imaging modality><imaging system><improved><in vivo><innovate><innovation><innovative><instrument><instrumentation><interest><machine based learning><microscope imaging><microscopic imaging><microscopy imaging><mosaic><multidisciplinary><neuro-sensory><neurosensory><new drug treatments><new drugs><new pharmacological therapeutic><new therapeutics><new therapy><next generation therapeutics><non-invasive imaging><noninvasive imaging><novel><novel drug treatments><novel drugs><novel pharmaco-therapeutic><novel pharmacological therapeutic><novel therapeutics><novel therapy><ocular surface><optical><optical Doppler tomography><optical coherence Doppler tomography><phase 2 study><phase II study><programs><prototype><resolutions><standard of care><three dimensional><three-dimensional visualization><tool><tumor><vision impairment><vision loss><visual loss><visually impaired>